Reference is made to the stock exchange announcement on 30 November 2023, where Nordhealth AS (the "Company") launched an offer to purchase up to 1,000,000 of its own shares through a reverse book building process (the "Offering").
The application period expired at 16:30 hours (CET) on 6 December 2023. Following the end of the application period, the Company has resolved to buy 992,624 shares at a price of NOK 23.00 per share, which equals approximately NOK 22.8 million in total.
All offers to sell shares with limits at or below NOK 23.00 have been allocated in full.
Allocation notifications will be sent to shareholders having tendered shares in the Offering on or about 7 December 2023. The trade date is expected to be on or about 7 December 2023 and the settlement date is expected to be on or about 11 December 2023.
The settlement will be conducted on a normal delivery-versus-payment basis (DVP). Following settlement of the Offering, the Company will own 1,146,637 shares in the Company. The Company currently has 80,191,746 shares outstanding.
For further information, please contact:
Carnegie AS
nordhealth@carnegie.no or +47 22 00 93 40
Charles Macbain, CEO
charles.macbain@nordhealth.com
Mari Orttenvuori, CFO
mari.orttenvuori@nordhealth.com
About Nordhealth
Nordhealth is a publicly listed, fast-growing cloud-based healthcare SaaS company on a mission to redefine digital healthcare. We build software that empower veterinary and therapy professionals to provide the best possible care experiences to their patients. Our products serve more than 50,000 veterinary and therapy professionals across 13,000 clinics and hospitals located in over 30 countries.
Headquartered in Helsinki, Finland, Nordhealth has a solid footprint in the Nordic region and a growing presence internationally, with more than 380 employees working either remotely or from offices (collaboration hubs). Visit the company's website at nordhealth.com (http://www.nordhealth.com).